- Home
- STI vs UNCY Comparison
STI vs UNCY Comparison
Compare STI & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STI
- UNCY
- Stock Information
- Founded
- STI 2014
- UNCY 2016
- Country
- STI United States
- UNCY United States
- Employees
- STI N/A
- UNCY N/A
- Industry
- STI
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- STI
- UNCY Health Care
- Exchange
- STI NYSE
- UNCY Nasdaq
- Market Cap
- STI 51.2M
- UNCY 58.7M
- IPO Year
- STI N/A
- UNCY 2021
- Fundamental
- Price
- STI $0.12
- UNCY $0.61
- Analyst Decision
- STI
- UNCY Strong Buy
- Analyst Count
- STI 0
- UNCY 3
- Target Price
- STI N/A
- UNCY $5.33
- AVG Volume (30 Days)
- STI 35.6M
- UNCY 789.1K
- Earning Date
- STI 04-08-2025
- UNCY 05-12-2025
- Dividend Yield
- STI N/A
- UNCY N/A
- EPS Growth
- STI N/A
- UNCY N/A
- EPS
- STI N/A
- UNCY N/A
- Revenue
- STI $5,329.00
- UNCY N/A
- Revenue This Year
- STI N/A
- UNCY N/A
- Revenue Next Year
- STI N/A
- UNCY N/A
- P/E Ratio
- STI N/A
- UNCY N/A
- Revenue Growth
- STI 32.73
- UNCY N/A
- 52 Week Low
- STI $0.12
- UNCY $0.20
- 52 Week High
- STI $4.44
- UNCY $1.60
- Technical
- Relative Strength Index (RSI)
- STI 28.71
- UNCY 51.64
- Support Level
- STI $0.13
- UNCY $0.60
- Resistance Level
- STI $0.14
- UNCY $0.69
- Average True Range (ATR)
- STI 0.02
- UNCY 0.05
- MACD
- STI 0.01
- UNCY 0.00
- Stochastic Oscillator
- STI 2.68
- UNCY 52.69
About STI SOLIDION TECHNOLOGY INC
Solidion Technology Inc is engaged in researching, developing and manufacturing battery materials and components, as well as the development and production of next-generation batteries for energy storage systems and electric vehicles for ground, air, and sea transportation. It is recognized as a global IP leader in both the high-capacity anode and the high-energy solid-state battery.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's lead drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury.